Searchable abstracts of presentations at key conferences in endocrinology

ea0025p103 | Clinical biochemistry | SFEBES2011

Testosterone undecanoate has a beneficial effect on lipid profile in men with hypogonadism in routine clinical practice

Muraleedharan Vakkat , Rolfe Christen , Ranjan Nishant , Jones Hugh

Background: There is a close association between low testosterone and metabolic syndrome. Testosterone replacement therapy (TRT) has beneficial effects on cardiovascular (CV) risk factors in men with hypogonadism.Aim: This is a retrospective audit of CV parameters in hypogonadal men treated with testosterone undecanoate (Nebido) in standard clinical practice.Methods: Patients with hypogonadism on testosterone undecanoate injections...

ea0016p111 | Clinical cases | ECE2008

Androgenic alopecia and hirsutism in a 73-year-old woman: careful re-evaluation of ‘normal' imaging findings may lead to a rare diagnosis

Christen Annette , Tischler Verena , Diener Pierre-Andre , Brandle Michael

A 73-year-old woman developed androgenic alopecia and progressive hair growth on the chest, back and abdomen over the course of 3–4 years. Menarche was at age 16. She had irregular menstrual periods subsequently but gave birth to three children. She reached menopause at age 40. No history of weight loss or sweating was reported. At presentation, we saw a 73-year-old lady with pronounced hirsutism (Ferriman–Gallway-score 24/36). No virilizing signs of the external gen...

ea0010p20 | Clinical case reports/Governance | SFE2005

New onset diabetes associated with the atypical antipsychotic olanzapine

Mehta S , Hameed A , Patel D , Christen A , Mather H , Valabhji J

Schizophrenia is associated with higher risk of Type 2 diabetes. There are several reports of Type 2 diabetes presenting as diabetic ketoacidosis, particularly in young obese African-Caribbean subjects. We report 3 cases of new onset diabetes presenting with diabetic ketoacidosis (see Table 1) in African-Caribbean males treated with olanzapine for chronic schizophrenia.Table 1 Metabolic parameters on admissionCase</td...

ea0041gp113 | Endocrine Tumours | ECE2016

FOXM1 as chemo-sensitizing target in neuroendocrine lung tumors

Christen Friederike , Grass Irina , Worpenberg Lina , Lewens Florentine , Briest Franziska , Siegmund Britta , Grabowski Patricia

Introduction: Neuroendocrine tumors of the lung (BP-NETs) are fairly rare tumors with very heterogeneous behavior and molecular characteristics. They are very heterogeneous concerning their malignancy, ranging from slow proliferating carcinoids (typical (TC) and atypical carcinoids (ATC)) to very aggressive large cell neuroendocrine carcinomas (LCNEC) and small cell lung cancers (SCLC). For the highly proliferative BP-NETs, combined chemotherapy is the standard therapy option,...

ea0041ep617 | Endocrine tumours and neoplasia | ECE2016

Dual inhibition of PI3K and mTORC1/C2 by PKI-587 (PF-05212384) as a promising therapeutic option for pulmonary neuroendocrine tumor disease

Broker Vanessa , Freitag Helma , Christen Friederike , Briest Franziska , Siegmund Britta , Grabowski Patricia

Background: Pulmonary neuroendocrine neoplasms are heterogeneous in their clinical behavior and therapeutic options are still not satisfactory. The ‘crosstalk’ of different signaling pathways in NEN cells appears to be more complex as known already. PKI-587 is a highly potent novel dual inhibitor of PI3K and mTORC1/C2.Aim: Therefore, we assessed the effects of PKI-587 in different pulmonary NEN cell lines compared to the established mTORC1 inhi...